Industry News
Broadvector acquires CSIRO prostate cancer vaccine IP
Broadvector has completed acquisition of IP from CSIRO for early-stage prostate cancer therapy and prostate cancer vaccine, with CSIRO becoming a major shareholder in the company. [ + ]
Mesoblast posts successful results from diabetes stem cell trial
A pre-clinical animal trial of Mesoblast's (ASX:MSB) stem cell treatment for Type 2 diabetes has shown positive results, with phase II trial planned for 2012. [ + ]
Sunshine Heart sees positive results in heart pump trial
Feasibility trial shows Sunshine Heart's (ASX:SHC) C-Pulse heart pump significantly improved heart function, setting the stage for more thorough testing in 2012. [ + ]
AusBiotech announces formation of the AusMedtech Health Economics Expert Panel
A new health economics panel has been launched to advise on key issues affecting medical devices companies regarding the assessment and reimbursement of medical devices diagnostics in Australia. [ + ]
Malaria vaccine wins Gates Foundation grant
A carbohydrate-based malaria vaccine developed by Australian researchers has won a US$1 million grant from the Bill & Melinda Gates Foundation. [ + ]
QRxPharma gets target date for MoxDuo IR FDA approval
Pending approval by the FDA, QRxPharma's (ASX:QRX) MoxDuo IR could be given the go ahead for sale by June 25 2012. [ + ]
Prof Bruce McKellar to head international physics union
Australian Academy of Science Fellow Professor Bruce McKellar has been elected as the next President of the IUPAP.
[ + ]AusBiotech and PwC webcast gives update on the state of the nation's biotechnology sector
The latest in the series of webcasts that discuss the latest happenings in the sector with AusBiotech and the results of PricewaterhouseCoopers' (PwC) BioForum quarterly report is out now. [ + ]
Feature: New pathways for cancer therapy
Associate Professor Stuart Pitson has been delving into the world of sphingolipid-mediated cell signalling pathways, particularly their enticing possibilities in cancer treatment. [ + ]
Immuron submits IND for liver disease drug
Immuron (ASX:IMC) to commence phase IIb clinical trial for drug to treat fatty liver disease, including Nonalcoholic steatohepatitis (NASH). [ + ]
Alchemia to spin off oncology business
Alchemia (ASX:ACL) intends to create new wholly-owned oncology business to develop chemotherapy drug delivery technology, HyACT. [ + ]
Circadian to start phase I trials for cancer drug after receiving IND approval
Circadian (ASX:CIR) to initiate phase I trials after receiving investigational new drug status from the Food and Drug Administration for VGX-100 anti-cancer drug. [ + ]
Clinuvel’s Scenesse sees positive trial results
A phase II study of Clinuvel’s (ASX:CUV) photoprotective Scenesse shows it is effective and safe in treating the rare disorder, erythropoietic protoporphyria (EPP). [ + ]
New Commonwealth committee for government research investments
Prof Ian Chubb will chair a new Commonwealth committee to guide government research investment.
[ + ]
